EXCILYNT (Melanoma)

EXCILYNT (Melanoma)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if surgically removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing melanoma from coming back in the same area of the lymph node excision. We also want to learn more about the side effects of this type of surgery and how it can impact patients' quality of life.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with melanoma that has spread to only one lymph node in the axilla (underarm area), groin, or iliac basin (pelvic region)
  • Are able to undergo lymph node excision
  • Have not had a lymph node dissection
For more information about who can join this study, please contact the study team at chandler.warren@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will have your enlarged lymph node removed during your planned cancer removal surgery. We wil keep in touch with you after this surgery to keep tabs on how you are doing. During this time, you will:
  • Have blood draws
  • Have physical exams
  • Have imaging scans (PET/CT and MRI)
  • Fill out surveys

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

Lymph Node Excision (LNEx) for Patients with Stage III Melanoma with One Clinically Positive Node: Excision of Lymph Node Trial [EXCILYNT]

Principal Investigator

Jay
Lee

Protocol Number

PRO00114693

NCT ID

NCT05839912

Phase

II

Enrollment Status

Open to Enrollment